02084nam a2200361 4500 ESSALUD 20260820161112.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Bhoj, Vijay G. Autor 54193 Kidney transplantation in two highly sensitized candidates after CAR T-Cell therapy páginas: 2117-2125 HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desensitization) have had inconsistent efficacy and have often failed to produce sustained reductions in anti-HLA antibodies in patients with the highest level of sensitization (calculated panel-reactive antibody score, ≥99.9%). We now report the results for the safety run-in cohort of a multicenter phase 1 clinical study evaluating the safety and efficacy of combined CD19-targeted and B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cells in eliminating the cellular sources of preformed anti-HLA antibodies (ClinicalTrials.gov number, NCT06056102). Kidney transplantation was performed in two highly sensitized candidates after desensitization with the use of dual CAR T-cell therapy. ENFERMEDAD RENAL CRÓNICA 32213 TRASPLANTE DE RIÑÓN 13898 CIRUGÍA GENERAL 44496 CÉLULAS T 54097 TRASPLANTE 7847 Kaminski, María 54194 Zhao, Huiwu 54195 Jackson, Kyle 54196 Wang, Wei 54197 Liu, Chengyang 54198 Montgomery, Robert A. 54199 Ali, Nicole 54200 Mangiola, Massimo 54201 Spitzer, Thomas R. 54202 Safa, Kassem 54203 22717 22648 Massachusetts NEJM Group NEJM011 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-08-20 sqb 22842 22842